NO20010576L - Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav - Google Patents

Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav

Info

Publication number: NO20010576L
Authority: NO; Norway
Prior art keywords: antigens; hsv; cells; immunological; methods
Prior art date: 1998-08-07

Application number

NO20010576A

Other languages

English (en)

Norwegian (no)

Other versions

NO20010576D0 (no

Inventor

David M Koelle

Lawrence Corey

Original Assignee

Univ Washington

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-07

Filing date

2001-02-02

Publication date

2001-04-02

2001-02-02 Application filed by Univ Washington filed Critical Univ Washington

2001-02-02 Publication of NO20010576D0 publication Critical patent/NO20010576D0/no

2001-04-02 Publication of NO20010576L publication Critical patent/NO20010576L/no

Links

239000000427 antigen Substances 0.000 title abstract 7
102000036639 antigens Human genes 0.000 title abstract 7
108091007433 antigens Proteins 0.000 title abstract 7
241000700584 Simplexvirus Species 0.000 title 1
230000001900 immune effect Effects 0.000 title 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 3
208000009889 Herpes Simplex Diseases 0.000 abstract 2
210000004027 cell Anatomy 0.000 abstract 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
230000000840 anti-viral effect Effects 0.000 abstract 1
210000003679 cervix uteri Anatomy 0.000 abstract 1
239000000470 constituent Substances 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
230000003902 lesion Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
102000040430 polynucleotide Human genes 0.000 abstract 1
108091033319 polynucleotide Proteins 0.000 abstract 1
239000002157 polynucleotide Substances 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Virology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20010576A 1998-08-07 2001-02-02 Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav NO20010576L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9572398P	1998-08-07	1998-08-07
US9572498P	1998-08-07	1998-08-07
PCT/US1999/017803 WO2000008051A2 (fr)	1998-08-07	1999-08-05	Antigenes immunologiques de l'herpes simplex virus

Publications (2)

Publication Number	Publication Date
NO20010576D0 NO20010576D0 (no)	2001-02-02
NO20010576L true NO20010576L (no)	2001-04-02

Family

ID=26790525

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20010576A NO20010576L (no)	1998-08-07	2001-02-02	Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav

Country Status (16)

Country	Link
US (5)	US6375952B1 (fr)
EP (2)	EP1102790B1 (fr)
JP (1)	JP2002522451A (fr)
KR (1)	KR20010085348A (fr)
CN (1)	CN1348463A (fr)
AR (1)	AR020134A1 (fr)
AU (1)	AU5467899A (fr)
BR (1)	BR9912671A (fr)
CA (1)	CA2336523C (fr)
DK (1)	DK2272859T3 (fr)
IL (1)	IL141044A0 (fr)
NO (1)	NO20010576L (fr)
NZ (1)	NZ509974A (fr)
PL (1)	PL346213A1 (fr)
TR (1)	TR200100373T2 (fr)
WO (1)	WO2000008051A2 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030185830A1 (en) *	1997-02-25	2003-10-02	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
US20060024301A1 (en) *	1997-02-25	2006-02-02	Corixa Corporation	Prostate-specific polypeptides and fusion polypeptides thereof
US7517952B1 (en)	1997-02-25	2009-04-14	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
US6375952B1 (en) *	1998-08-07	2002-04-23	University Of Washington	Immunological herpes simplex virus antigens and methods for use thereof
GB2375113B (en)	2000-01-21	2004-10-20	Biovex Ltd	A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
US7217770B2 (en) *	2000-05-17	2007-05-15	Samyang Corporation	Stable polymeric micelle-type drug composition and method for the preparation thereof
US6821519B2 (en)	2000-06-29	2004-11-23	Corixa Corporation	Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US7048931B1 (en) *	2000-11-09	2006-05-23	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
ATE488249T1 (de)	2001-07-31	2010-12-15	Univ Washington	Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung
DK1523582T3 (da)	2002-07-18	2009-03-02	Univ Washington	Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
CA2538794C (fr) *	2003-09-12	2016-04-19	Antigenics, Inc.	Vaccin pour le traitement et la prevention de l'infection provoquee par le virus de l'herpes simplex
US7211272B2 (en) *	2003-12-22	2007-05-01	Bausch & Lomb Incorporated	Drug delivery device
CA2658484A1 (fr) *	2006-07-20	2008-01-24	Vical Incorporated	Compositions et methodes de vaccination contre le hsv-2
WO2008030560A2 (fr) *	2006-09-08	2008-03-13	The Trustees Of The University Of Pennsyvania	Vaccins contre le hsv-1 et le hsv-2 et méthodes d'utilisation
EP2185145A1 (fr)	2007-04-04	2010-05-19	Board of Trustees of the University of Arkansas	Réponse d'hypersensibilité de type retardé non spécifique pour traiter une infection par le virus de l'herpès simplex
US8460674B2 (en)	2009-02-07	2013-06-11	University Of Washington	HSV-1 epitopes and methods for using same
US9044447B2 (en)	2009-04-03	2015-06-02	University Of Washington	Antigenic peptide of HSV-2 and methods for using same
EP3756684A1 (fr)	2009-05-22	2020-12-30	Genocea Biosciences, Inc.	Vaccins contre le virus de l'herpès simplex de type 2 : compositions et procédés pour obtenir une réponse immunitaire
WO2012061637A2 (fr) *	2010-11-03	2012-05-10	University Of Washington	Épitopes du vhs-1 et leurs méthodes d'utilisation
JP6055776B2 (ja)	2010-11-24	2016-12-27	ジェノセアバイオサイエンシーズ，インコーポレイテッド	単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
WO2012112691A1 (fr)	2011-02-15	2012-08-23	Immune Design Corp.	Procédés d'amélioration des réponses immunitaires spécifiques d'un immunogène avec des vaccins vectorisés
EA027236B1 (ru) *	2011-04-08	2017-07-31	Иммьюн Дизайн Корп.	Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
US20120288515A1 (en) *	2011-04-27	2012-11-15	Immune Design Corp.	Synthetic long peptide (slp)-based vaccines
JP6205360B2 (ja) *	2011-08-22	2017-09-27	ナノバイオコーポレーション	単純ヘルペスウイルスのナノエマルジョンワクチン
AU2012340712B2 (en)	2011-11-23	2017-09-14	Genocea Biosciences, Inc.	Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
HRP20181102T1 (hr) *	2012-05-16	2018-09-07	Immune Design Corp	Cjepiva za hsv-2
WO2014164699A1 (fr) *	2013-03-11	2014-10-09	The Regents Of The University Of California	Vaccins et traitements contre le virus de l'herpès
ES2738582T3 (es)	2014-02-14	2020-01-23	Immune Design Corp	Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica
KR20170032373A (ko)	2014-07-15	2017-03-22	이뮨 디자인 코포레이션	Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
KR20160073707A (ko)	2014-12-17	2016-06-27	삼성중공업 주식회사	액화천연가스 운반선의 운용방법
CN107427540A (zh)	2015-02-26	2017-12-01	斯垮瑞斯有限责任公司	用于治疗单纯疱疹病毒感染的非特异性延迟型过敏反应
DK3411388T3 (da) *	2016-02-01	2021-12-13	Simplexia Ab	Trunkeret glycoprotein g af herpes simplex virus 2
CN118949021A (zh) *	2016-03-14	2024-11-15	雷德生物科技股份公司	用于治疗hsv的手段和方法
MX2018012472A (es)	2016-04-15	2019-08-12	Alpine Immune Sciences Inc	Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
WO2017181152A2 (fr)	2016-04-15	2017-10-19	Alpine Immune Sciences, Inc.	Protéines immunomodulatrices à variants de cd80 et leurs utilisations
WO2018022946A1 (fr)	2016-07-28	2018-02-01	Alpine Immune Sciences, Inc.	Protéines immunomodulatrices à variants de cd155 et leurs utilisations
US11471488B2 (en)	2016-07-28	2022-10-18	Alpine Immune Sciences, Inc.	CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (fr)	2016-07-28	2018-02-01	Alpine Immune Sciences, Inc.	Protéines immunomodulatrices à variants de cd112 et utilisations associées
US10350288B2 (en)	2016-09-28	2019-07-16	Genocea Biosciences, Inc.	Methods and compositions for treating herpes
EP3596116B1 (fr)	2017-03-16	2023-09-06	Alpine Immune Sciences, Inc.	Protéines immunomodulatrices de variants de pd-l1 et utilisations associées
KR20190141146A (ko)	2017-03-16	2019-12-23	알파인 이뮨 사이언시즈, 인코포레이티드	Pd-l2 변이체 면역조절 단백질 및 그의 용도
SG11201907769XA (en)	2017-03-16	2019-09-27	Alpine Immune Sciences Inc	Cd80 variant immunomodulatory proteins and uses thereof
KR20260047644A (ko)	2017-03-30	2026-04-08	더 유니버서티 어브 퀸슬랜드	키메라 분자 및 그의 용도
US20190031739A1 (en) *	2017-07-30	2019-01-31	Raymond Joel Rairie	Pinball herpes antibody system
EP3687561A4 (fr)	2017-09-01	2021-06-09	The Australian National University	Molécules immunorégulatrices et leurs utilisations
JP7749319B2 (ja)	2017-10-10	2025-10-06	アルパインイミューンサイエンシズインコーポレイテッド	Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
BR112020007542A2 (pt)	2017-10-18	2020-12-01	Alpine Immune Sciences, Inc.	proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
AU2019205273B2 (en)	2018-01-03	2024-04-04	Alpine Immune Sciences, Inc.	Multi-domain immunomodulatory proteins and methods of use thereof
WO2019241758A1 (fr)	2018-06-15	2019-12-19	Alpine Immune Sciences, Inc.	Protéines immunomodulatrices de variants de pd-l1 et utilisations associées
EP3853247A2 (fr)	2018-09-19	2021-07-28	Alpine Immune Sciences, Inc.	Méthodes et utilisations de protéines de fusion de variant cd80 et constructions associées
CA3120868A1 (fr)	2018-11-30	2020-06-04	Alpine Immune Sciences, Inc.	Proteines immunomodulatrices a variants cd86 et leurs utilisations
MX2021012607A (es)	2019-04-17	2022-03-11	Alpine Immune Sciences Inc	Metodos y usos de proteinas de fusion de ligando icos (icosl) variante.
EP4146684A2 (fr)	2020-05-08	2023-03-15	Alpine Immune Sciences, Inc.	Protéines immunomodulatrices inhibitrices de baff et april avec et sans protéine inhibitrice des lymphocytes t et leurs procédés d'utilisation
US20240279310A1 (en)	2021-05-07	2024-08-22	Alpine Immune Sciences, Inc.	Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
WO2023172883A1 (fr)	2022-03-07	2023-09-14	Alpine Immune Sciences, Inc.	Protéines immunomodulatrices de polypeptides cd80 variants, thérapies cellulaires associées et méthodes et utilisations associés
CN115808528B (zh) *	2022-09-21	2023-08-01	武汉滨会生物科技股份有限公司	溶瘤单纯疱疹病毒vp5蛋白与人白细胞抗原e的互作方法及应用
KR20250099778A (ko)	2022-10-04	2025-07-02	알파인 이뮨 사이언시즈, 인코포레이티드	자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질
CN119874937B (zh) *	2025-01-14	2025-09-05	绿竹生物制药(珠海市)有限公司	一种重组i型单纯疱疹病毒疫苗及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4429008B1 (en)	1981-12-10	1995-05-16	Univ California	Thiol reactive liposomes
US4603112A (en)	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
US4769330A (en)	1981-12-24	1988-09-06	Health Research, Incorporated	Modified vaccinia virus and methods for making and using the same
US4436727A (en)	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
US4866034A (en)	1982-05-26	1989-09-12	Ribi Immunochem Research Inc.	Refined detoxified endotoxin
JPS59116229A (ja)	1982-12-24	1984-07-05	Teijin Ltd	細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4873088A (en)	1983-09-06	1989-10-10	Liposome Technology, Inc.	Liposome drug delivery method and composition
US4859587A (en)	1984-06-04	1989-08-22	Institut Merieux	Recombinant herpes simplex viruses, vaccines and methods
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
GB8508845D0 (en)	1985-04-04	1985-05-09	Hoffmann La Roche	Vaccinia dna
US4777127A (en)	1985-09-30	1988-10-11	Labsystems Oy	Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
US4699784A (en)	1986-02-25	1987-10-13	Center For Molecular Medicine & Immunology	Tumoricidal methotrexate-antibody conjugate
US4877611A (en)	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
US5075109A (en)	1986-10-24	1991-12-24	Southern Research Institute	Method of potentiating an immune response
GB8702816D0 (en)	1987-02-07	1987-03-11	Al Sumidaie A M K	Obtaining retrovirus-containing fraction
EP0297924A3 (fr) *	1987-07-01	1990-07-11	City Of Hope	Virus de la vaccine recombinant exprimant la glycoproteine HSV 1 gB
US4897268A (en)	1987-08-03	1990-01-30	Southern Research Institute	Drug delivery system and method of making the same
WO1989001973A2 (fr)	1987-09-02	1989-03-09	Applied Biotechnology, Inc.	Virus variolique recombinant d'immunisation contre des antigenes associes a une tumeur
AP129A (en)	1988-06-03	1991-04-17	Smithkline Biologicals S A	Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
AU648261B2 (en)	1989-08-18	1994-04-21	Novartis Vaccines And Diagnostics, Inc.	Recombinant retroviruses delivering vector constructs to target cells
SE466259B (sv)	1990-05-31	1992-01-20	Arne Forsgren	Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2088600C (fr)	1990-08-02	1999-11-16	Rae L. Burke	Vaccins antiherpetiques fabriques a partir de l'epitope vp16 du virus
JPH05236967A (ja) *	1991-05-07	1993-09-17	Medical Res Council	ヘルペスウイルス粒子及びワクチン
CA2090295A1 (fr)	1992-02-03	1993-08-04	Anthony B. Nesburn	Procede pour l'expression de la glycoproteine e du virus de l'herpes simplex de type-1 et methodes d'utilisation
CA2138997C (fr)	1992-06-25	2003-06-03	Jean-Paul Prieels	Composition vaccinale qui contient des adjuvants
US5426039A (en)	1993-09-08	1995-06-20	Bio-Rad Laboratories, Inc.	Direct molecular cloning of primer extended DNA containing an alkane diol
GB9325496D0 (en) *	1993-12-14	1994-02-16	Smithkline Beecham Biolog	Vaccines
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
EP1167379A3 (fr)	1994-07-15	2004-09-08	University Of Iowa Research Foundation	Oligonucléotides immunomodulateurs
EP0811057B1 (fr) *	1995-02-21	2006-04-26	Cantab Pharmaceuticals Research Limited	Preparations virales, vecteurs, immunogenes et vaccins correspondants
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ATE365808T1 (de)	1995-07-28	2007-07-15	Marie Curie Cancer Care	Transportproteine und deren verwendungen
EP0871747A1 (fr)	1996-01-02	1998-10-21	Chiron Viagene, Inc.	Immunostimulation a mediation par cellules dendritiques modifiees par des genes
GB9615726D0 (en) *	1996-07-26	1996-09-04	Medical Res Council	Anti-viral agent 11
CA2270282A1 (fr) *	1996-11-04	1998-05-14	Smithkline Beecham Corporation	Nouvelles sequences codantes pour le virus herpes simplex de type 2
EP0984790A1 (fr) *	1997-06-02	2000-03-15	Chiron Corporation	Vaccins au vp22 contre le virus de l'herpes simplex et procede d'utilisation de ces vaccins
US6375952B1 (en) *	1998-08-07	2002-04-23	University Of Washington	Immunological herpes simplex virus antigens and methods for use thereof
GB9825953D0 (en) *	1998-11-26	1999-01-20	Medical Res Council	Protein fragments for use in protein targeting
EP1222281B1 (fr) *	1999-09-30	2006-11-15	University of Washington	Antigenes du virus herpes simplex immunologiquement importants
US6821519B2 (en) *	2000-06-29	2004-11-23	Corixa Corporation	Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
DK1523582T3 (da) *	2002-07-18	2009-03-02	Univ Washington	Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
CA2658484A1 (fr) *	2006-07-20	2008-01-24	Vical Incorporated	Compositions et methodes de vaccination contre le hsv-2
US8865185B2 (en) *	2006-09-08	2014-10-21	The Trustees Of The University Of Pennsylvania	Methods of use for HSV-1 and HSV-2 vaccines

1999
- 1999-08-05 US US09/368,770 patent/US6375952B1/en not_active Expired - Lifetime
- 1999-08-05 BR BR9912671-0A patent/BR9912671A/pt not_active IP Right Cessation
- 1999-08-05 TR TR2001/00373T patent/TR200100373T2/xx unknown
- 1999-08-05 AU AU54678/99A patent/AU5467899A/en not_active Abandoned
- 1999-08-05 NZ NZ509974A patent/NZ509974A/en not_active IP Right Cessation
- 1999-08-05 EP EP99940918.8A patent/EP1102790B1/fr not_active Expired - Lifetime
- 1999-08-05 EP EP10182295.5A patent/EP2272859B1/fr not_active Expired - Lifetime
- 1999-08-05 PL PL99346213A patent/PL346213A1/xx not_active Application Discontinuation
- 1999-08-05 DK DK10182295.5T patent/DK2272859T3/en active
- 1999-08-05 CN CN99810454A patent/CN1348463A/zh active Pending
- 1999-08-05 WO PCT/US1999/017803 patent/WO2000008051A2/fr not_active Ceased
- 1999-08-05 JP JP2000563684A patent/JP2002522451A/ja not_active Withdrawn
- 1999-08-05 KR KR1020017001641A patent/KR20010085348A/ko not_active Abandoned
- 1999-08-05 IL IL14104499A patent/IL141044A0/xx unknown
- 1999-08-05 CA CA2336523A patent/CA2336523C/fr not_active Expired - Fee Related
- 1999-08-06 AR ARP990103950A patent/AR020134A1/es not_active Application Discontinuation
2001
- 2001-02-02 NO NO20010576A patent/NO20010576L/no unknown
2002
- 2002-02-11 US US10/073,834 patent/US6855317B2/en not_active Expired - Fee Related
2005
- 2005-02-10 US US11/055,477 patent/US7744903B2/en not_active Expired - Fee Related
2010
- 2010-05-10 US US12/777,156 patent/US8067010B2/en not_active Expired - Fee Related
2011
- 2011-10-18 US US13/276,166 patent/US8852602B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1348463A (zh)	2002-05-08
NO20010576D0 (no)	2001-02-02
US20030118611A1 (en)	2003-06-26
EP2272859A2 (fr)	2011-01-12
WO2000008051A3 (fr)	2000-08-03
US20050163794A1 (en)	2005-07-28
US7744903B2 (en)	2010-06-29
AU5467899A (en)	2000-02-28
PL346213A1 (en)	2002-01-28
NZ509974A (en)	2003-10-31
EP1102790A2 (fr)	2001-05-30
DK2272859T3 (en)	2015-01-19
TR200100373T2 (tr)	2001-09-21
US6375952B1 (en)	2002-04-23
CA2336523C (fr)	2015-06-30
EP1102790B1 (fr)	2014-05-07
IL141044A0 (en)	2002-02-10
US20120027790A1 (en)	2012-02-02
US20100215693A1 (en)	2010-08-26
JP2002522451A (ja)	2002-07-23
EP2272859A3 (fr)	2011-06-08
AR020134A1 (es)	2002-04-10
US6855317B2 (en)	2005-02-15
US8852602B2 (en)	2014-10-07
CA2336523A1 (fr)	2000-02-17
US8067010B2 (en)	2011-11-29
EP2272859B1 (fr)	2014-10-22
KR20010085348A (ko)	2001-09-07
WO2000008051A2 (fr)	2000-02-17
BR9912671A (pt)	2001-05-02

Publication	Publication Date	Title
NO20010576L (no)	2001-04-02	Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav
BR0014408A (pt)	2002-07-02	Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos
Vollmar et al.	2006	Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine
Osterhaus et al.	1999	Vaccination with Rev and Tat against AIDS
Schat et al.	2000	Specific and nonspecific immune responses to Marek’s disease virus
Lubinski et al.	1999	In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC
Clements et al.	1995	The epidemiology of measles: thirty years of vaccination
ES2224655T3 (es)	2005-03-01	Vacuna antiviral recombinante de la encefalitis equina venezolana.
HK1047297A1 (en)	2003-02-14	Herpes virus strains
WO2003011893A3 (fr)	2003-09-12	Antigenes du virus de l'herpes simplex (hsv) importants d'un point de vue immunologiques et procedes d'utilisation correspondants
WO1998037095A3 (fr)	1998-11-19	Poxvirus recombine destine a une immunisation contre l'antigene associe aux tumeurs muc1
ATE332965T1 (de)	2006-08-15	Komplementierende zellinien
UA84667C2 (ru)	2008-11-25	Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
US20240156951A1 (en)	2024-05-16	Vaccine compositions and methods for treating hsv
CA2245545A1 (fr)	1997-08-14	Produit vaccinal issu du gene 63 actif contre le virus varicelle-zona
CA2254082A1 (fr)	1997-11-13	Vaccin contre le cancer recto-colique metastatique
WO2000057904A3 (fr)	2001-01-18	Vaccin a base de virus de dengue-3 attenue
Fernández‐Parrado et al.	2023	Monkeypox vaccine: Special considerations for dermatologic patients.
Lasky	1990	From virus to vaccine: recombinant mammalian cell lines as substrates for the production of herpes simplex virus vaccines
WO2025212851A3 (fr)	2025-11-13	Compositions d'arnm et leurs utilisations dans des vaccins contre le virus varicelle-zona
AU5489500A (en)	2001-01-02	Isolation of a human retrovirus
WO2003017943A3 (fr)	2005-01-13	Compositions therapeutiques et methodes de traitement d'infections virales
CA2562136A1 (fr)	2005-10-27	Nouveau virus de la bursite infectieuse et vaccin contenant le virus
KR20250171986A (ko)	2025-12-09	β-D-글루칸을 포함하는 아쥬반트 조성물 및 이를 포함하는 백신 조성물
Hanke	2001	Vehicles for Genetic Vaccines Against Human Immunodeficiency Virus Induction of T Cell-mediated Immune Responses